Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.83 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.83 |
| ▸ | NCOR2 | Q9Y618 | 11/20 | 0.83 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.83 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.83 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.83 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.83 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.83 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.83 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.83 |
| ▸ | TET3 | O43151 | 1/20 | 0.83 |
| ▸ | BRD4 | O60885 | 1/20 | 0.83 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.83 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.83 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.83 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255503 | 1.00 | HDAC1 (0.83) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| SCHEMBL31087946 | 1.00 | HDAC1 (0.83) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| SCHEMBL4349158 | 1.00 | HDAC1 (0.83) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| Hydrochloric Acid SCHEMBL19743942 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| Bromide SCHEMBL20165852 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| Oxalic Acid SCHEMBL20165841 | 0.98 | HDAC1 (0.80) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| SCHEMBL4380126 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| Panobinostat SCHEMBL22773814 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| Panobinostat SCHEMBL164801 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| SCHEMBL4380122 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222115-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-20240299555-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2024-09-12 | — | — | US | disclosed |
| EP-4380575-A1 | DRUG CONJUGATES OF SUGAR DERIVATIVES AND USES THEREOF AS SENOLYTIC AGENTS | Rubedo Life Sciences, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023039600-A1 | DRUG CONJUGATES OF SUGAR DERIVATIVES AND USES THEREOF AS SENOLYTIC AGENTS | Rubedo Life Sciences, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20210299154-A1 | Senolytic Compositions And Uses Thereof | Rubedo Life Sciences, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-20210299154-A1 | Senolytic Compositions And Uses Thereof | Rubedo Life Sciences, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-11026963-B2 | Senolytic compositions and uses thereof | Rubedo Life Sciences, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2017221163-A1 | NOVEL SALTS AND POLYMORPHIC FORMS OF PANOBINOSTAT | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2017-12-28 | — | — | WO | disclosed |
| EP-2032531-B1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2032532-B1 | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-2032532-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-Ý4-ÝÝÝ2-(2-METHYL-1H-INDOL-3-YL)ETHYL¨AMINO¨METHYL¨PHENYL¨-2E-2-PROPENAMIDE | Novartis AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146717-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299154-A1 | Senolytic Compositions And Uses Thereof | SENP3, SENP6, SENP1 | HDAC1 1056/4885HDAC2 1020/4885HDAC3 273/4885 |
| US-11026963-B2 | Senolytic compositions and uses thereof | SENP3, SENP6, SENP1 | HDAC1 1056/4885HDAC2 1020/4885HDAC3 273/4885 |
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | AGER, SENP6, SENP3 | HDAC1 861/4885HDAC2 1138/4885HDAC3 207/4885 |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | SENP3, SENP6, SENP1 | HDAC1 1056/4885HDAC2 1020/4885HDAC3 273/4885 |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
| US-20240299555-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | AGER, SENP6, SENP3 | HDAC1 861/4885HDAC2 1138/4885HDAC3 207/4885 |
| US-20250222115-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | AGER, SENP6, SENP3 | HDAC1 861/4885HDAC2 1138/4885HDAC3 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.